He is the CEO & CSO of NovaMechanics Ltd. Dr Afantitis has a strong scientific background in the field of chemoinformatics, bioinformatics and medicinal chemistry. The main field of the application of his research is drug discovery, property design and prediction. Recently he has developed a virtual activity procedure in order to develop potent therapeutic agents for the treatment of different diseases by understaning the interactions at the molecular level.

His research mainly focuses on the development of tools that are able to derive high quality molecular descriptors and to efficiently manage huge amounts of available data in order to link Structure-Based Drug Design, Cheminformatics and Bioinformatics. He is a reviewer in leading scientific journals (Journal of Molecular Graphics and Modeling, Chemometrics and Intelligent Laboratory Systems, European Journal of Medicinal Chemistry,  Molecular Diversity, Chromatographia, Molecules  & Molecular Simulation, Expert Opinion On Drug Discovery) and an evaluator of international competitive grants.

Additionally Dr. Afantitis has managerial experience in large scale scientific projects since he has managed successfully EU funded projects (total budget over 11 M euros).  His scientific work has been published in more than 21 original research articles in international peer reviewed journals.